Biomarin Pharmaceutical reported $26.19M in Pre-Tax Profit for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Pre Tax Profit Change
Acadia Pharmaceuticals ACAD:US $ -112.57M 69.67M
Agios Pharmaceuticals AGIO:US $ -94.77M 3.81M
Alnylam Pharmaceuticals ALNY:US $ -239.36M 20.95M
Amgen AMGN:US $ 2727M 56M
Biogen BIIB:US $ 903.4M 316.6M
Biomarin Pharmaceutical BMRN:US $ 26.19M 92.76M
Bluebird Bio BLUE:US $ -122.15M 10.09M
Insmed INSM:US $ -94236000 18.78M
Intercept Pharmaceuticals ICPT:US $ -17.28M 19M
IONIS PHARMACEUT IONS:US $ -64M 289M
Moderna Inc MRNA:US 4.23B 1.18B
Neurocrine Biosciences NBIX:US $ 21.4M 35.2M
Ptc Therapeutics PTCT:US $ -121.89M 16.72M
Regeneron Pharmaceuticals REGN:US $ 1119.1M 1986M
Sangamo Biosciences SGMO:US $ -43.92M 6.36M
Sarepta Therapeutics SRPT:US $ -104.15M 17.74M
Seattle Genetics SGEN:US $ -135.24M 41.73M
Ultragenyx Pharmaceutical RARE:US $ -151.76M 29.32M
United Therapeutics UTHR:US $ 308.7M 168.2M
YTE INCY:US $ 172.84M 1.75M